Media
Press releases
-
Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit
STOCKHOLM — September 8, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has eliminated an organizational layer to ... -
Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma – 495 patients included
STOCKHOLM — September 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in ... -
FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
STOCKHOLM — August 29, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted prior... -
INTERIM REPORT Q2 2020
Summary Financial overview April 1 – June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0 M (loss: 171.9) Loss per s...